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Abstract
Background: Kaposi sarcoma (KS) flare may occur following therapy with corticosteroids, as part
of the immune reconstitution inflammatory syndrome seen with highly active antiretroviral therapy
(HAART), and after rituximab therapy. The exact mechanism responsible for iatrogenic KS flare is
unclear.
Methods:  A case of AIDS-associated cutaneous KS flare following rituximab therapy was
compared to similar controls by means of immunohistochemistry using vascular makers (CD34,
CD31), monoclonal antibodies to Human Herpesvirus 8 (HHV8) gene products (LNA-1, K5), as
well as B-lymphocyte (CD20) and T-lymphocyte (CD3, CD4, CD8) markers.
Results: CD20+ B-cell depletion with rituximab in KS flare occurred concomitantly with activation
of the HHV8 immediate early gene protein K5. KS flare in this patient was successfully treated with
liposomal doxorubicin and valganciclovir.
Conclusion: Rituximab-induced KS flare appears to be related to HHV8 activation. Effective
management of iatrogenic KS flare therefore depends upon the control of HHV8 viremia in
conjunction with specific chemotherapy for KS.
Background
Kaposi sarcoma (KS) is a multifocal, angioproliferative
tumor related to Kaposi's Sarcoma Herpesvirus/Human
Herpesvirus-8 (KSHV/HHV8) infection. HHV8 is a mem-
ber of the gamma-herpesvirinae sub-family, in which gene
expression and viral replication are regulated by latent,
immediate early, early, and late viral gene transcription
[1]. During latency, certain viral genes such as the Latency-
associated nuclear antigen (LANA or ORF73) are critical
for replication and maintenance of the HHV8 episome in
latently infected cells. Immediate early genes (e.g. K3 and
K5) code for transcriptional activators and are critical for
initiating viral transcription [2]. K5, also known as modu-
lator of immune recognition 2 (MIR2), is a transmem-
brane-spanning ubiquitin-ligase that mediates the
ubiquitination of cytoplasmic proteins of other trans-
membrane proteins, such as major histocompatibility
complex-I (MHC-I) molecules. Down regulation of MHC-
I molecules by K5 gene expression during reactivation is
important for evading the host's immune system, because
this process inhibits the presentation of viral antigen to
cytotoxic T cells [2].
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Histologically, KS lesions are comprised of spindled
shaped tumor cells, abnormal vessels and a variable
chronic lymphoplasmacytic inflammatory infiltrate. KS
lesions grow from an early patch stage, to form plaques,
which ultimately develop into a nodular (tumor) stage.
Most of the cells found in both KS lesions and HHV8-
infected cultures are latently infected [3], although both
lytic and latent phases of the HHV8 life cycle play signifi-
cant roles in the pathogenesis of KS. In only a small per-
centage of infected cells is lytic replication of HHV8
observed [3].
KS exacerbation (flare or recrudescence) has been docu-
mented following therapy with corticosteroids [4-6], as
part of the immune reconstitution inflammatory syn-
drome (IRIS) seen with highly active antiretroviral ther-
apy (HAART) in HIV-infected persons [7-9], and after
treatment with rituximab [10-13]. Rituximab is a chimeric
murine/human immunoglobulin G anti-CD20 mono-
clonal antibody that mediates cytotoxicity against CD20+
B-cells. In the setting of human immunodeficiency virus
(HIV) infection, rituximab has been increasingly used to
treat multicentric Castleman disease (MCD). In a recent
uncontrolled phase II study involving 21 patients with
MCD that were treated with rituximab, 4 of the 11
patients (36%) who had cutaneous KS experienced pro-
gression of their KS lesions [13]. The exact mechanism(s)
responsible for KS flare are unclear, and likely involve
HHV8 activation and/or alteration of the host immune
system.
We present, for the first time, the pathology of rituximab-
induced KS flare. By means of immunohistochemistry, we
set out to study the potential role of host immunity, as
well as that of specific HHV8 gene products, in the patho-
genesis of KS flare.
Methods
Institutional Review Board approval from Baystate Medi-
cal Center and Beth Israel Deaconess Medical Center was
obtained for this study. Informed consent was obtained
from the patient to perform this study and publish the
findings.
Clinical case features
A 36-year-old homosexual man known to be HIV-positive
for two years presented with fever (104°F), chills, drench-
ing night sweats, lassitude, diffuse myalgias and arthral-
gias. He had been started on HAART several months prior
to this presentation, which was discontinued due to the
development of a rash. Prior to the initiation of HAART,
his CD4 T-cell count was 363 cells/mm3 and his HIV viral
load was greater than 100,000 copies/ml. His physical
examination was notable for massive lymphadenopathy
involving cervical, occipital, supraclavicular, axillary,
groin and epitrochlear areas with lymph nodes measuring
up to 1 cm in diameter. A CT scan also demonstrated
marked lymphadenopathy of his chest, abdomen, and
pelvis. Biopsy of an axillary node confirmed MCD, con-
taining HHV8 (LNA-1) immunoreactive lymphoid cells.
Treatment was begun with prednisone 1 mg/kg to control
his symptoms, and rituximab 375 mg/m2 once weekly for
4 consecutive weeks as definitive treatment for MCD. One
week after starting rituximab, he developed a biopsy-
proven KS plaque lesion on his leg (Figure 1 and 2), and
another on his back. The patient continued his treatment
of rituximab for MCD, was restarted on HAART for HIV
infection, began liposomal doxorubicin for KS, and
started daily valganciclovir for his HHV8 infection. He
had rapid and dramatic normalization of all abnormali-
ties, including resolution of his lymphadenopathy and
complete disappearance of KS lesions.
Immunohistochemistry
The aforementioned patient's biopsy was compared to
similar (control) cutaneous plaque-stage KS lesions from
two AIDS patients with stable KS disease. Formalin fixed,
paraffin embedded routinely processed tissue was stud-
ied. The antibodies and dilutions used are summarized in
Table 1. K5 mouse monoclonal antibody (Ab13.c5) is not
commercially available, and was raised in the laboratory
of one the authors (KF) against the c-terminal recom-
binant fragment of K5. All primary antibodies were
diluted in Dako antibody diluent. Heat induced epitope
Cutaneous Kaposi sarcoma lesion, plaque stage (H&E stain;  original magnification ×100) Figure 1
Cutaneous Kaposi sarcoma lesion, plaque stage (H&E stain; 
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retrieval was performed in Biogenex Citra buffer (plus
buffer for LNA-1) for 10 minutes at 98°C. All immunohis-
tochemistry was performed on a Dako Autostainer using
a Signet Acuity kit (from Covance). H2O2 was used after
antigen retrieval to block endogenous peroxidases for all
antibodies except CD4 and CD8, in order not to com-
pletely inhibit staining in these two primary antibodies.
All slides were then counter stained with hematoxylin.
The immunoreactivity between our patient's KS flare
lesion and the controls were compared.
Results
The histomorphology of the KS flare case and that of the
controls was unremarkable. In all specimens, CD34 and
CD31 similarly highlighted spindled tumor cells and the
abnormal vasculature within these lesions. LNA-1 nuclear
granular immunoreactivity was of equal intensity and
proportion in scattered KS tumor cells of all specimens.
However, K5 staining was identified only in occasional
cells (Figure 3) from the patient with KS flare. In the two
control cases, both CD3 and CD20 cells were present,
with a preponderance of T-lymphocytes identified. In the
KS flare specimen, there were only T-cells present with a
notable absence of B-lymphocytes (Figure 4). In all three
cases T-cell subsets showed CD8 > CD4.
Discussion
KS flare and/or exacerbation is a relatively newly
described phenomenon related to the use of corticoster-
oids, HAART, and/or rituximab therapy. Although our
patient received a combination of these drugs, his KS flare
was temporally associated most closely with rituximab
therapy. Moreover, he did not have other clinical features
to support IRIS, such as a marked increase in CD4+ lym-
phocyte count and decreased plasma HIV-1 viral load
after receiving HAART. While the initiation of HAART is
most often associated with KS regression, there have cer-
tainly been accounts of KS flare following antiretroviral
treatment. In one series involving nine patients with IRIS,
the mean time to onset of KS flare was 5 weeks [9]. To the
best of our knowledge, no studies have yet examined the
actual pathogenesis of KS flare as a manifestation of IRIS.
Table 1: List of antibodies used for immunohistochemistry of Kaposi sarcoma.
Antibody Intended use Source Dilution
CD34 Endothelial marker Dako M765 Mouse monoclonal 1:500
CD31 Endothelial marker Dako M0823 Mouse monoclonal 1:200
LNA-1 Latent HHV8 infection Vector VP-H913 Rabbit polyclonal 1:40
K5 Lytic HHV8 infection Ab13.c5 Mouse monoclonal 1:1000
CD3 T-lymphocytes Dako A0452 Rabbit polyclonal 1:200
CD4 Helper T-cell subset Vector VP-C318 Mouse monoclonal 1:20
CD8 Cytotoxic T-cell subset Vector VP-C324 Mouse monoclonal 1:40
CD20 B-lymphocytes Dako M0755 Mouse monoclonal 1:3000
Higher power magnification of Kaposi sarcoma lesion show- ing infiltrating plump spindled tumor cells admixed with  blood vessels and a sparse mononuclear inflammatory infil- trate (H&E stain; original magnification ×400) Figure 2
Higher power magnification of Kaposi sarcoma lesion show-
ing infiltrating plump spindled tumor cells admixed with 
blood vessels and a sparse mononuclear inflammatory infil-
trate (H&E stain; original magnification ×400).BMC Clinical Pathology 2008, 8:7 http://www.biomedcentral.com/1472-6890/8/7
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To date, only a limited number of publications have
reported KS flare and/or rapid progression in patients
treated with rituximab [13]. One paper documented the
brisk progression of classic KS in an 80-year-old man who
was receiving prednisone and rituximab for severe
autoimmune hemolytic anemia [12]. KS progression in
this individual only occurred two weeks after completing
rituximab infusions. His lesions did not regress, even
months after stopping rituximab. Other investigators
observed in responders to rituximab for HIV-associated
MCD an aggravation of KS, even though the HIV-1 load
and CD4 cell count in these individuals were unaffected
[14].
The mechanism for KS development due to rituximab is
undefined. Some authors postulate that by specifically
depleting B cells, rituximab likely affects T-cell function
(by eliminating B- and T-cell interactions), thereby facili-
tating KS development [12]. Other researchers found that
clinical relapse of HIV-associated MCD in individuals
who failed rituximab therapy was associated with
increased blood HHV8 DNA levels and a worsening of KS
[15]. In our study, we identified two unique findings in KS
flare following rituximab; viz. the depletion of all lesional
B lymphocytes and concomitant expression of the HHV8
gene product K5.
Lymphocytes are an integral component of KS tumors.
Peripheral lymphocytes, particularly B-cells, are also the
major latent reservoirs of HHV8. As compared to normal
skin, KS tumors typically contain a high density of CD3+
T-lymphocytes, and fewer CD20+ B-lymphocytes [16]. In
fact, the vast majority of KS infiltrating lymphocytes are of
CD3+ CD8+ immunophenotype [17]. The evolution of
KS from early to advanced disease is associated with a
gradual decrease in the number of total and B lym-
phocytes. This is supported by a study involving 68
patients with classic KS, in which investigators found a
statistically significant reduction in B-lymphocyte counts
in individuals with advanced-stage KS (79/microL) com-
pared with those in earlier stages of the disease (224/
microL) [18]. Nadir B-cell counts in a similar study of HIV
infected persons also documented an association with an
increased risk of KS development [19]. Higher B-cell
counts in this study of HIV-infected persons appeared to
actually have a protective effect against the formation of
KS lesions [19]. Therefore, it is easy to appreciate why B-
cell depletion due to rituximab therapy in our case
resulted in unwanted KS flare.
Exactly how B-cell depletion causes KS growth is most
likely related to HHV8. Rituximab has previously been
noted to cause Hepatitis B reactivation with related fulmi-
nant hepatitis [20]. In vivo, HHV8 within KS exists in a
predominantly latent state, with less than 5% of infected
Comparison of the inflammatory component between con- trol (left) and KS flare (right) specimens Figure 4
Comparison of the inflammatory component between con-
trol (left) and KS flare (right) specimens. Both lesions exhibit 
admixed T-cells (CD3), whereas only the KS flare tumor has 
a complete absence of B-cells (CD20).
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K5 immunoreactivity is shown in occasional tumor cells  (arrows) in this KS flare lesion (K5 immunohistochemical  stain; original magnification ×400) Figure 3
K5 immunoreactivity is shown in occasional tumor cells 
(arrows) in this KS flare lesion (K5 immunohistochemical 
stain; original magnification ×400).BMC Clinical Pathology 2008, 8:7 http://www.biomedcentral.com/1472-6890/8/7
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cells expressing discernible lytic gene products. After stim-
ulation, HHV8 can enter the lytic cycle by a reactivation
process. Increased expression of the immediate early gene
product K5 in KS flare tumor cells identified in our study
may indicate HHV8 activation. In general, K5 is more fre-
quently identified within advanced KS tumors compared
to early KS lesions (unpublished observation). This
explains why K5 was not identified in our control speci-
mens of plaque stage. K5 is a modulator of immune rec-
ognition (ubiquitin ligase) that helps HHV8 evade the
host's immune system during lytic replication [21].
Conclusion
Our data demonstrate that B-cell depletion with rituxi-
mab in patient's at risk for KS development may activate
HHV8, resulting in unwanted KS flare. Given the expand-
ing therapeutic use of rituximab, caution is required when
using this monoclonal antibody in patients at risk for
developing KS. Nevertheless, in HHV8+ patients with
MCD we feel that rituximab is still the treatment of choice.
Finally, based upon the resolution of our patient's KS flare
following appropriate therapy, effective management of
iatrogenic KS flare appears to depend upon the control of
HHV8 viremia in conjunction with chemotherapy for KS.
Valganciclovir, when administered for 8 weeks, has been
demonstrated in a randomized placebo-controlled trial to
suppress HHV8 replication [22]. Although short term use
of valganciclovir in patients who test positive for HHV8
could be considered, its clinical benefit has not been
proven. Further work is required to better understand the
interaction between B-cells and the lymphotropic HHV8.
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